We are live on ! Find out more
EDSA icon

Edesa Biotech

20 hedge funds and large institutions have $6.89M invested in Edesa Biotech in 2025 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,127% more capital inflows, than outflows

Capital inflows: $5.97M | Capital outflows: $268K

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

34.4% more ownership

Funds ownership: 5.98% → 40.38% (+34%)

18% more funds holding

Funds holding: 17 → 20 (+3)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
20
Holders Change
+3
Holders Change %
+17.65%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
2
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

EDSA Hedge Fund Activity: Q1 2025 in Review

20 of the 7,489 institutional investors tracked by Wall St. Rank reported a position in Edesa Biotech (EDSA) for Q1 2025, worth a combined $6.89M — up 1,867% from $350K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new EDSA positions and 3 closed out — a net gain of 4 holders — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Rubric Capital Management (New York), opening a new position worth an estimated $1.48M. The largest seller was CM Management, exiting entirely with an estimated $185K sold.

  • 20 institutional investors held Edesa Biotech (EDSA) as of Q1 2025, up from 17 in Q4 2024.
  • Funds reported $6.89M of Edesa Biotech stock for Q1 2025, up 1,867% quarter-over-quarter.
  • 7 funds opened new Edesa Biotech positions in Q1 2025 and 3 closed out, a net change of +4 holders.
  • The largest Edesa Biotech buyer in Q1 2025 was Rubric Capital Management (New York), an estimated $1.48M added.
  • The largest Edesa Biotech seller in Q1 2025 was CM Management, an estimated $185K sold.

Based on aggregated 13F filings for Q1 2025.